TheraVida, SK Chemicals to develop THVD-201 and THVD-202 for OAB, UUI

Wednesday, April 3, 2013

TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida’s proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). 

[Read More]

Marken opens pharmaceutical depot in Beijing

Monday, March 11, 2013

Marken, a global clinical supply chain solutions provider, has completed its new pharmaceutical depot in Beijing, China. The new facility which provides 850 square meters of GMP compliant space for temperature controlled storage as well as distribution of clinical trial supplies is co-located with the existing Marken Beijing branch office to provide a fully integrated and best in class service to clients.

[Read More]